Autolus Therapeutics (AUTL) Return on Sales (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Return on Sales for 9 consecutive years, with 0.04% the latest figure, recorded in Q4 2025.

• Quarterly Return on Sales rose 948.0% year-over-year to 0.04% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.04% (up 18.0% YoY) and the FY2025 annual result came in at 0.04%, up 18.0% from the prior year.
• Return on Sales steadied at 0.04% in Q4 2025 per AUTL's latest filing, from 0.04% in the prior quarter.
• Over the last five years, Return on Sales for AUTL reached as high as 0.02% in Q2 2025 and fell as low as 9.52% in Q4 2024.
• A 5-year average of 1.15% and a median of 0.25% in 2024 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales tumbled 829 bps — and 2025, when it surged 948 bps.
• Year by year, Return on Sales stood at 0.71% in 2021, then surged by 90 bps to 0.07% in 2022, then tumbled by 1564 bps to 1.23% in 2023, then sank by 676 bps to 9.52% in 2024, then soared by 100 bps to 0.04% in 2025.
• According to Business Quant data, Return on Sales over the past three periods registered 0.04%, 0.04%, and 0.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.